Barbara Pahud’s Post

This week, Pfizer has made major strides in our efforts to help prevent respiratory syncytial virus (RSV) in older adults and infants. I’m thrilled to share that today, Pfizer announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the granting of a marketing authorization for Pfizer’s RSV vaccine candidate for both older adults and infants through maternal immunization. If approved, it would be the first and only vaccine to help prevent RSV in both of these high-risk populations. Read more here: https://lnkd.in/emH6SYUq. This positive opinion comes on the heels of the first dose of Pfizer’s RSV vaccine being administered in the U.S. for older adults. These milestones underscore Pfizer’s expertise in vaccine research and development and represent a significant step forward in our efforts to help prevent this highly infectious and potentially serious disease.   Thank you to all of my colleagues at Pfizer who helped us achieve these goals - your resounding commitment to developing new, innovative vaccines inspires me every day.

For years the world has needed a seasonal influenza (flu) vaccine that works better to protect our communities against hospitalization, severe cases, and the countless deaths from the virus. I’m pleased to share that just this week we’ve started here at Pfizer our late-stage Phase 3 study for our mRNA-based flu vaccine. This is the first ever Phase 3 program to understand the efficacy of an mRNA-based vaccine in comparison to the vaccine available for use today. I’m personally excited about this moment as we hope that an mRNA vaccine will give us more flexibility to update seasonal influenza vaccines on an ongoing basis and potentially manufacture the vaccine in half the amount of time than the current flu vaccine. Our experience with RNA viruses and mRNA technology has given us an even deeper understanding of the opportunity with this platform and I’m very much looking forward to advancing this study next to the hundreds of people here in Vaccine Research & Development and across Pfizer who are focused on this work that could change global health outcomes. https://lnkd.in/efqz2UZW

Time is running out! ⌛ The Ethical Considerations in Research for Pediatric Populations virtual conference starts tomorrow! Featured speaker, Alison Bateman-House of NYU Grossman School of Medicine stresses that "this is an active, live conversation happening right now - to which nobody has the answers. That's why it's so important that all of us engage in this conversation." Learn more about this 2-day virtual event and tune into Alisons's panel, "N of 1 in Genomics and Rare Disease Research" alongside Steve Usdin, Biocentury, Stanley Crooke, n-Lorem Foundation Timothy Yu, Boston Children's Hospital, Harvard Medical School and Julia Ortega, iHope / Genetic Alliance Can't make it live? All registrants will be offered direct, on-demand streaming access to each speaking session.

Hot Topic: COVID-19 Research in Children This highly anticipated panel at the Ethical Considerations in Research for Pediatric Populations conference features Art Caplan from NYU Grossman School of Medicine, Lindsay McNair, MD, MPH, MSB from WIRB-Copernicus Group, Barbara Pahud from Pfizer, Roberta L. DeBiasi from Children's National Hospital, and C. Buddy Creech from Vanderbilt University. Don't miss out, register to join this 2-day convening this September. https://lnkd.in/dJJQ28JD